NOVO B clawed back 4% on the week to DKK 280.30, but the rebound sits inside a month that is still down 6.3% — and the stock's own scoring system keeps flashing a warning that short-term relief does not erase longer structural pressure.
The borrowing market offers almost nothing for bears to work with here. Availability is extraordinarily loose — nearly 5,000% of short interest is covered by shares still available to lend, meaning roughly 972 million shares sit ready to borrow against a very thin short position. That points to a lending pool with almost no tension whatsoever. Cost to borrow has eased alongside it, falling 16% on the week to just 1.06% — a level consistent with a large-cap stock that attracts minimal speculative shorting. The ORTEX short score confirms this: at 27.9, it ranks in the 91st percentile for low short-squeeze risk, meaning the stock looks deeply un-crowded from a short-seller's perspective. Whatever is weighing on Novo Nordisk, it is not aggressive short-side positioning.
The score picture tells a more complicated story. The ORTEX momentum component has collapsed to 40.7 — sharply below where it stood even a month ago — and the stock is trading at roughly 54% of its 52-week high, leaving deeply negative relative strength across every major lookback window. Growth remains the standout, supported by a five-year EBIT CAGR above 30% and recent year-on-year sales expansion near 8%. Quality holds firm too, with return on assets near 19%. But momentum is dragging the total ORTEX score toward its six-month low, and the gap with GLP-1 rival Eli Lilly — which scores around 76.7 on momentum versus Novo's 40.7 — captures how sharply sentiment has diverged between the two most direct competitors in the space. Valuation multiples have drifted lower: the P/E has slipped roughly 0.34 points over 30 days and the P/B has compressed by 0.21, consistent with a stock that is being re-rated downward without a clear earnings-driven catalyst to arrest the move.
On the Street, the formal analyst data is too stale to cite meaningfully — the most recent consensus figures are from 2023, making any published price target unreliable relative to today's DKK 280 price. What the narrative record does carry is a clear bull-bear split that has been playing out in the market itself. Bulls point to Ozempic and Wegovy's dominance of the GLP-1 category, a pipeline expanding into adjacent indications, and a dividend score ranking in the 98th percentile — one of the strongest in the large-cap pharma universe. Bears focus on semaglutide pricing pressure, the acceleration of oral obesity therapy competition, and a stock that has now underperformed peers like HLUN B — down nearly 2% on the week — and the broader pharma group for a sustained stretch. The EV/EBITDA multiple has edged down 0.15 points over the past seven days, suggesting some incremental valuation relief but not a decisive re-rating.
Institutional ownership underlines how anchored the register is. Novo Holdings holds 28.3% of shares and reported zero change at year-end. Norges Bank Investment Management added nothing over the same period. Among more active managers, Dodge & Cox filed a fresh position of 35.6 million shares as of March 31, and Capital Research added nearly 12.7 million shares through May 29 — both meaningful additions that suggest some longer-duration money is stepping in at these levels, even as momentum remains weak.
The next hard date is the Q2 earnings release on August 5. The most recent comparable print, in May, produced a 3.4% one-day gain and a 4.7% five-day follow-through — the sole recent upside surprise in a history that also includes a 3.1% one-day drop after the March 2026 results. Whether the August print replicates the constructive May reaction or reverts to the earlier negative pattern will likely depend on whether management can shift the narrative away from competitive risk and back toward pipeline progress — that is the tension the market will be pricing into the weeks ahead.
See the live data behind this article on ORTEX.
Open NOVO B on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
